318 related articles for article (PubMed ID: 33917069)
1. Application of Janus Kinase Inhibitors in Atopic Dermatitis: An Updated Systematic Review and Meta-Analysis of Clinical Trials.
Tsai HR; Lu JW; Chen LY; Chen TL
J Pers Med; 2021 Apr; 11(4):. PubMed ID: 33917069
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis.
Li C; Sun X; Zhao K; Meng F; Li L; Mu Z; Han X
Dermatology; 2022; 238(4):725-735. PubMed ID: 34455413
[TBL] [Abstract][Full Text] [Related]
3. Short-term efficacy and safety of biologics and Janus kinase inhibitors for patients with atopic dermatitis: A systematic review and meta-analysis.
Chen Q; Cui L; Hu Y; Chen Z; Gao Y; Shi Y
Heliyon; 2023 Nov; 9(11):e22014. PubMed ID: 38034798
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of abrocitinib for the treatment of moderate-to-severe atopic dermatitis: a meta-analysis of randomized clinical trials.
Meher BR; Mohanty RR; Padhy BM
J Dermatolog Treat; 2022 Jun; 33(4):2335-2343. PubMed ID: 34315323
[TBL] [Abstract][Full Text] [Related]
5. Janus kinase inhibitors in atopic dermatitis: an umbrella review of meta-analyses.
He Q; Xie X; Chen Q; Li W; Song Z; Wang X; Ma X; Zeng J; Guo J
Front Immunol; 2024; 15():1342810. PubMed ID: 38464512
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of topical Janus kinase and phosphodiesterase inhibitor-4 inhibitors for the treatment of atopic dermatitis: A network meta-analysis.
Zhang L; Du D; Wang L; Guo L; Jiang X
J Dermatol; 2021 Dec; 48(12):1877-1883. PubMed ID: 34487567
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of Janus kinase inhibitors in patients with atopic dermatitis: A systematic review and network meta-analysis.
Zhang L; Wang L; Jiang X
Dermatol Ther; 2021 Sep; 34(5):e15098. PubMed ID: 34392600
[TBL] [Abstract][Full Text] [Related]
8. Topical tacrolimus for atopic dermatitis.
Cury Martins J; Martins C; Aoki V; Gois AF; Ishii HA; da Silva EM
Cochrane Database Syst Rev; 2015 Jul; 2015(7):CD009864. PubMed ID: 26132597
[TBL] [Abstract][Full Text] [Related]
9. Oral Janus kinase inhibitors in the treatment of atopic dermatitis: A systematic review and meta-analysis.
Lee KP; Plante J; Korte JE; Elston DM
Skin Health Dis; 2023 Feb; 3(1):e133. PubMed ID: 36751339
[TBL] [Abstract][Full Text] [Related]
10. The effectiveness of Janus kinase inhibitors in treating atopic dermatitis: A systematic review and meta-analysis.
Arora CJ; Khattak FA; Yousafzai MT; Ibitoye BM; Shumack S
Dermatol Ther; 2020 Jul; 33(4):e13685. PubMed ID: 32463149
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of JAK inhibitors for atopic dermatitis: a systematic review and meta-analysis.
Miao M; Ma L
J Dermatolog Treat; 2022 Jun; 33(4):1869-1877. PubMed ID: 34132163
[TBL] [Abstract][Full Text] [Related]
12. Emerging Role of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis.
Singh R; Heron CE; Ghamrawi RI; Strowd LC; Feldman SR
Immunotargets Ther; 2020; 9():255-272. PubMed ID: 33204661
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial.
Gooderham MJ; Forman SB; Bissonnette R; Beebe JS; Zhang W; Banfield C; Zhu L; Papacharalambous J; Vincent MS; Peeva E
JAMA Dermatol; 2019 Dec; 155(12):1371-1379. PubMed ID: 31577341
[TBL] [Abstract][Full Text] [Related]
14. Safety considerations of systemic Janus kinase inhibitors in atopic dermatitis applications.
Chang PH; Huang SF; Chang PS; Yu Y
J Dermatol; 2021 Nov; 48(11):1631-1639. PubMed ID: 34462967
[TBL] [Abstract][Full Text] [Related]
15. The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and network meta-analysis.
Alves C; Penedones A; Mendes D; Batel Marques F
Eur J Clin Pharmacol; 2022 Dec; 78(12):1923-1933. PubMed ID: 36207461
[TBL] [Abstract][Full Text] [Related]
16. Major adverse cardiovascular events in patients with atopic dermatitis treated with oral Janus kinase inhibitors: a systematic review and meta-analysis.
Ertus C; Scailteux LM; Lescoat A; Berthe P; Auffret V; Dupuy A; Oger E; Droitcourt C
Br J Dermatol; 2023 Sep; 189(4):368-380. PubMed ID: 37410552
[TBL] [Abstract][Full Text] [Related]
17. The suitability of treating atopic dermatitis with Janus kinase inhibitors.
Narla S; Silverberg JI
Expert Rev Clin Immunol; 2022 May; 18(5):439-459. PubMed ID: 35377276
[TBL] [Abstract][Full Text] [Related]
18. Dupilumab treatment in moderate-to-severe atopic dermatitis: A systematic review and meta-analysis.
Wang FP; Tang XJ; Wei CQ; Xu LR; Mao H; Luo FM
J Dermatol Sci; 2018 May; 90(2):190-198. PubMed ID: 29472119
[TBL] [Abstract][Full Text] [Related]
19. Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE-052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis.
Nakagawa H; Nemoto O; Yamada H; Nagata T; Ninomiya N
J Dermatol; 2018 Jun; 45(6):701-709. PubMed ID: 29665062
[TBL] [Abstract][Full Text] [Related]
20. Systematic review and meta-analysis of randomized clinical trials (RCTs) comparing topical calcineurin inhibitors with topical corticosteroids for atopic dermatitis: A 15-year experience.
Broeders JA; Ahmed Ali U; Fischer G
J Am Acad Dermatol; 2016 Aug; 75(2):410-419.e3. PubMed ID: 27177441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
